mirdametinib
mirdametinib: sourced relationships with 1 company · 12 clinical trials tracked.
mirdametinib evidence translation
What we can confirm
12 tracked trials
What it means
What to watch
Prepared research question
How could mirdametinib → SWTX affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| SpringWorks Therapeutics, Inc. (SWTX) Treatment of solid tumors harboring MAPK pathway aberrations… | Phase 2 |
Clinical Trial Registry Records (12)showing 10 most recent
Individual Patient Compassionate Use of Mirdametinib
A Phase 1b, Open-Label Study of Mirdametinib in Infants and Toddlers With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas
Primary endpoint: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
A Phase 1, Open-Label, Drug Interaction Study to Assess the Effects of Probenecid, a Probe UGT Enzyme Inhibitor, on the Pharmacokinetics of Mirdametinib and Its Metabolites in Healthy Participants
Primary endpoint: Geometric Mean Ratios of Mirdametinib Pharmacokinetic Plasma Concentration in Presence and Absence of Probenecid
Phase 1/2 Trial of Mirdametinib in Patients With MAPK Pathway Mutant Central Nervous System Tumors
Primary endpoint: Best overall neurologic response rate
A Phase 1, Open-Label Study to Assess the Enzyme Inducing Effects of Carbamazepine on the Pharmacokinetics of Mirdametinib and Its Metabolites in Healthy Participants
Primary endpoint: The geometric mean ratio of mirdametinib plasma area under the concentration-time curve from dosing extrapolated to infinity (AUCinf) of Mirdametinib
A Phase 1 Open-Label Study to Assess the Pharmacokinetics of Mirdametinib and Its Metabolite PD-0315209 in Participants With Impaired Hepatic Function and Participants With Normal Hepatic Function
Primary endpoint: Maximum plasma concentration (Cmax) of mirdametinib
A Phase Ib/II Study of the Mirdametinib in Combination With Palbociclib in Patients With Advanced Dedifferentiated Liposarcoma
Primary endpoint: Maximum tolerated dose (Phase I)
A Modular Open Label, Signal Seeking, Phase II Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations (TARGET-VM)
Primary endpoint: The number of participants who achieve or exceed a predetermined threshold of improvement in their most significant symptom at 48 weeks based on the Vascular Malformation Patient Specific Outcome Measure (VM-PSOM).
A Phase 1/2a Open-label, Multicenter Dose Finding Study to Evaluate the Safety and Anti-tumor Activity of Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).
Primary endpoint: Assess the safety of continuous and three week on-one week off dosing of mirdametinib in adults with NF1 and cutaneous neurofibromas (cNFs).
A Phase 1/2a Open-Label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Mirdametinib in Combination With BGB-3245 in Patients With Advanced Solid Tumors
Primary endpoint: Incidence of Treatment Emergent Adverse Events
Frequently asked questions
Which companies have sourced relationships with mirdametinib?
mirdametinib has dated SEC/FDA relationship records for SpringWorks Therapeutics, Inc..
How many clinical trials involve mirdametinib?
BioSniper tracks 12 clinical trials involving mirdametinib.